Asarina Pharma AB (publ)
ASRPF
Other OTC2.45
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- IPO Date
- Dec 30, 2019
- Similar Companies
- Business
- Asarina Pharma AB (publ) (ASRPF), a Swedish biotechnology company founded in 2005 and headquartered at Karolinska Institutet Science Park in Solna, Sweden, researches and develops pharmaceutical products targeting allopregnanolone-induced stress- and compulsivity-driven neurological disorders; its flagship product, Sepranolone, a patented endogenous GABA-A Modulating Steroid Antagonist (GAMSA), modulates the negative effects of allopregnanolone for the treatment of conditions including Tourette syndrome, obsessive-compulsive disorder, menstrual migraine, premenstrual dysphoric disorder, PTSD, compulsive gambling, and addiction, with positive Phase IIa topline results announced in May 2023 demonstrating a 28% reduction in tic severity, 69% greater quality-of-life improvement, 50% greater impairment reduction, and 44% greater premonitory urge reduction versus standard of care, alongside an excellent safety profile free of CNS off-target effects. The company operates primarily in Europe through its Nasdaq First North Growth Market-listed shares (ticker: ASAP, delisted October 2024) and a lean team of approximately seven, including subsidiaries Asarina Pharma ApS in Denmark holding Sepranolone intellectual property and Asarina Pharma Finans AB; it targets patients with unmet needs in neurological and women's health segments underserved by existing therapies like antipsychotics or SSRIs. In February 2025, Asarina sold all Sepranolone assets via an Asset Purchase Agreement to Relmada Therapeutics Inc., a US-based CNS disorder specialist advancing it toward a Phase IIb Tourette syndrome study, after which the board proposed voluntary liquidation effective July 1, 2025, following a directed share issue raising SEK 48 million in early 2025 and a SEK 1 million convertible loan from major shareholder Östersjöstiftelsen in November 2023 to fund partnering efforts amid challenging capital markets; shareholders approved liquidation at an extraordinary general meeting on April 22, 2025, with attorney Johan Klåvus appointed liquidator and proceeds distribution anticipated alongside the final report.